Latest / The Well-Built Life / Blood Sugar & Pancreatic Cancer: Early Signs & Screening Debates
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, and with me, as always, is Thomas Bennett.
- 0:07Speaker 1: We are so excited to dive into this fascinating topic today.
- 0:11Speaker 1: Let's cut through the noise and share practical insights that
- 0:14Speaker 1: can help you feel stronger and healthier. Grab a drink
- 0:18Speaker 1: and get comfortable. Let's dive in.
- 0:20Speaker 2: Absolutely, Rachel. Today, we will explore the timeline of research
- 0:24Speaker 2: connecting pancreatic cancer and blood sugar levels. It's been a
- 0:27Speaker 2: journey over the last decade, filled with intriguing findings and
- 0:31Speaker 2: important nuance.
- 0:32Speaker 1: Indeed, in 2009, Dr. Sunit Cherry and his team at
- 0:36Speaker 1: the Mayo Clinic published a groundbreaking case, control study. They
- 0:41Speaker 1: analyzed records from 736 patients with pancreatic cancer and 1875 controls,
- 0:48Speaker 1: tracking fasting glucose levels over a three-year period.
- 0:52Speaker 2: Right, and that's the crucial nuance. While they didn't find
- 0:55Speaker 2: significant differences initially, They noticed a gradual increase in glucose
- 1:00Speaker 2: levels leading up to diagnosis. It's not a sudden spike,
- 1:04Speaker 2: but a pattern that emerged over time.
- 1:06Speaker 1: Exactly. Fast forward to 2018, another study by the same
- 1:11Speaker 1: group in gastroenterology. They looked at 219 patients diagnosed with
- 1:16Speaker 1: pancreatic ductal adenocarcinoma. Now, Thomas, how does this play out
- 1:21Speaker 1: in practice? Did this study confirm the earlier findings or
- 1:25Speaker 1: offer new insights?
- 1:26Speaker 2: Good question, Rachel. This time, they found that fasting glucose
- 1:30Speaker 2: levels started to rise significantly about 30 to 36 months
- 1:34Speaker 2: before the diagnosis. That's quite a long window, isn't it?
- 1:38Speaker 1: Yes, a substantial timeline indeed. But it's the gradual nature
- 1:43Speaker 1: of this change that's critical. It's not a sudden onset,
- 1:48Speaker 1: but a slow and steady rise. almost like a slow
- 1:50Speaker 1: simmer before it boils over.
- 1:52Speaker 2: Precisely. And this raises more questions. For instance, in the
- 1:57Speaker 2: 2025 study, they flagged new onset diabetes as a marker,
- 2:02Speaker 2: diagnosing 82 patients over a median follow, a period of 2.3 years,
- 2:09Speaker 2: a 0.62% three-year incidence risk translates to about 1 in
- 2:15Speaker 2: 160 individuals.
- 2:16Speaker 1: That's a significant finding, but let's not jump to conclusions.
- 2:20Speaker 1: What do we make of this in the context of screening? Dr.
- 2:24Speaker 1: Bradley Wuss, 2020, study in JAMA Network, open-analyzed 851,402 individuals
- 2:31Speaker 1: from the Kaiser Permanente Southern California database. They found that
- 2:35Speaker 1: while HbA1c levels correlated with increased pancreatic cancer risk, the
- 2:40Speaker 1: screening tool was limited due to ethnic variations and high
- 2:44Speaker 1: false positive rates.
- 2:46Speaker 2: That's wild when you look at the numbers. While HbA1c
- 2:50Speaker 2: is a useful indicator, it's far from perfect. More than
- 2:54Speaker 2: 200 to 600 people would need to be screened to
- 2:57Speaker 2: find one case. This highlights the need for more sophisticated approaches.
- 3:02Speaker 1: Absolutely. In 2019, the U.S. Preventive Services Task Force reaffirmed
- 3:07Speaker 1: its stance on routine screening, emphasizing the risks of overdiagnosis
- 3:12Speaker 1: and unnecessary surgeries. Their comprehensive reviews highlighted the lack of
- 3:17Speaker 1: reliable evidence for routine screening.
- 3:19Speaker 2: So, the key takeaway is that while blood sugar levels
- 3:23Speaker 2: show promise, they haven't yet become a reliable screening tool.
- 3:27Speaker 2: We need to balance the potential for early detection with
- 3:30Speaker 2: the risks of overtesting. That leads us to the next
- 3:33Speaker 2: steps and ongoing research.
- 3:35Speaker 1: Exactly. Looking forward, the integration of blood glucose patterns with
- 3:40Speaker 1: other clinical symptoms and biomarkers could provide more tailored screening strategies.
- 3:47Speaker 1: Technological advancements in personalized medicine might offer more nuanced solutions,
- 3:53Speaker 1: but we are not there yet. We still have a
- 3:55Speaker 1: lot to learn.
- 3:56Speaker 2: You are right, Rachel. The Mayo Clinic studies detail a
- 3:59Speaker 2: significant time window, a full 30 to 36 months before diagnosis.
- 4:05Speaker 2: The glucose levels began to creep up gradually, crossing the
- 4:08Speaker 2: diabetic threshold around 6 to 12 months before diagnosis. It's
- 4:12Speaker 2: almost like a slow simmer before it boils over.
- 4:15Speaker 1: Yes, and the HbA1c levels are another marker. While they
- 4:19Speaker 1: correlated with increased risk, Dr. Wu's study found that screening
- 4:24Speaker 1: based on HbA1c alone was problematic. High false positive rates
- 4:29Speaker 1: and varied ethnic responses made it challenging to develop a
- 4:32Speaker 1: reliable screening tool.
- 4:33Speaker 2: So, when you look at the complexity, it's clear that
- 4:37Speaker 2: a single measure doesn't cut it. The Kaiser Permanente analysis
- 4:41Speaker 2: reinforced this. It showed that while HbA1c can be an indicator,
- 4:46Speaker 2: it isn't foolproof.
- 4:47Speaker 1: Agreed. We need to integrate multiple markers, perhaps including clinical
- 4:51Speaker 1: symptoms and other biomarkers, to get a more comprehensive picture.
- 4:56Speaker 1: Pancreatic cancer is a complex disease with varied etiologies.
- 5:00Speaker 2: Precisely, and the broader debate around over-diagnosis and over-treatment in
- 5:05Speaker 2: routine screening is critical. We need to ensure that any
- 5:09Speaker 2: new screening method is both sensitive and specific. We can't
- 5:13Speaker 2: just jump to mass testing without a solid evidence base.
- 5:16Speaker 1: Absolutely. The future lies in developing more sophisticated algorithms and
- 5:21Speaker 1: integrating technologies for better screening. After all, early detection could
- 5:26Speaker 1: save lives. But we must do so judiciously to avoid
- 5:30Speaker 1: unnecessary interventions.
- 5:32Speaker 2: Right. So while the research provides promising leads, we are
- 5:36Speaker 2: still a long way from having a reliable screening tool.
- 5:40Speaker 2: The journey is ongoing. But the step-by-step analysis and nuanced
- 5:44Speaker 2: understanding are crucial for moving forward.
- 5:46Speaker 1: That's the tricky part with blood sugar as a marker.
- 5:50Speaker 1: It's not a straightforward one-to-one relationship. Many people with diabetes
- 5:55Speaker 1: never develop pancreatic cancer, while some who do might not
- 5:59Speaker 1: show symptoms initially.
- 6:01Speaker 2: But the real value is in understanding the complex relationship
- 6:04Speaker 2: between blood sugar and pancreatic cancer. For instance, in the
- 6:08Speaker 2: 2025 study, They noted that the risk was highest in
- 6:11Speaker 2: the initial months after the onset of diabetes. That's a
- 6:15Speaker 2: specific and actionable window to watch out for.
- 6:18Speaker 1: Yes, and let's not forget about the HbA1c levels. While
- 6:22Speaker 1: they correlated with increased risk, the specific study by Dr.
- 6:26Speaker 1: Wu and colleagues found that screening based on HbA1c alone
- 6:30Speaker 1: was problematic. The false positive rates were high, and the
- 6:35Speaker 1: varied responses across different ethnic groups made it challenging to
- 6:38Speaker 1: develop a reliable screening tool.
- 6:40Speaker 2: That's when you need to question, is blood sugar alone
- 6:44Speaker 2: the best way to go? It's clear that a single
- 6:47Speaker 2: measure doesn't cut it. The Kaiser Permanente analysis highlighted this.
- 6:51Speaker 2: It showed that while HbA1c can be an indicator, it
- 6:55Speaker 2: isn't foolproof.
- 6:56Speaker 1: Exact. It makes sense that we need to integrate multiple markers,
- 7:01Speaker 1: perhaps including clinical symptoms and other biomarkers, to get a
- 7:05Speaker 1: more comprehensive picture. After all, Pancreatic cancer is a complex
- 7:10Speaker 1: disease with varied etiologies.
- 7:12Speaker 2: Precisely. And the broader debate around over-diagnosis and over-treatment in
- 7:16Speaker 2: routine screening is critical. We need to ensure that any
- 7:20Speaker 2: new screening method is both sensitive and specific. We can't
- 7:24Speaker 2: just jump to mass testing without a solid evidence base.
- 7:28Speaker 1: Absolutely. The future might involve integrating different biomarkers and technologies.
- 7:34Speaker 1: Maybe we will see more personalized approaches, based on lifestyle,
- 7:37Speaker 1: genetic factors, and other potential indicators. But for now, the
- 7:42Speaker 1: key is being cautious and not jumping into full-scale screening
- 7:45Speaker 1: programs without a solid evidence base.
- 7:48Speaker 2: Exactly. The journey is ongoing. As Dr. Cherry shares, we
- 7:52Speaker 2: still need more evidence to fully understand these patterns. The
- 7:56Speaker 2: future might lie in integrating a broader array of markers.
- 8:00Speaker 2: It's a marathon, not a sprint, in finding the right
- 8:03Speaker 2: balance for early detection.
- 8:05Speaker 1: And the stakes are high. So we must navigate carefully.
- 8:08Speaker 1: Until we hit that needle, we keep working, refining our approach,
- 8:12Speaker 1: and ensuring that any new screening methods are both effective
- 8:16Speaker 1: and patient-friendly.
- 8:17Speaker 2: True. This discussion reminds me of how we approached early
- 8:21Speaker 2: signs of cardiovascular disease, multifactorial and complex. We need a
- 8:26Speaker 2: system that's smart enough to distinguish the real risks without
- 8:29Speaker 2: setting off false positives.
- 8:31Speaker 1: Right. It's like walking a tightrope. We need to be
- 8:34Speaker 1: cautious and ensure that any screening protocols are designed to
- 8:39Speaker 1: catch early cases without causing undue stress.
- 8:43Speaker 2: Exactly. The strategic implications of this research are significant. With
- 8:48Speaker 2: more data coming in, we are closer to balanced screening approaches,
- 8:52Speaker 2: but we still need to tread carefully.
- 8:54Speaker 1: Yes. The key is in minimizing overdiagnosis while ensuring we
- 8:59Speaker 1: catch the disease early. It's not a simple matter. but
- 9:03Speaker 1: precision and tailored approaches can help.
- 9:06Speaker 2: Precisely. This is where the real research needs to go.
- 9:10Speaker 2: We need to understand the nuances, the edge cases, and
- 9:14Speaker 2: the variations between individuals. True. And the Kaiser Permanente study
- 9:19Speaker 2: shows that HbA1c alone isn't a reliable screening tool due
- 9:23Speaker 2: to varying responses across different ethnic groups. It's a complex web.
- 9:27Speaker 1: Absolutely. So, the next steps involve integrating multiple markers, Blood
- 9:33Speaker 1: glucose levels, clinical symptoms, and genetic markers could all play
- 9:37Speaker 1: a part.
- 9:38Speaker 2: Absolutely. And we should consider the real-world impact. How will
- 9:42Speaker 2: these screening protocols affect patient care and mental health? Overdiagnosis
- 9:47Speaker 2: can be a serious issue, leading to unnecessary anxiety and treatment.
- 9:51Speaker 1: Exactly. So, how do we ensure that the new screening
- 9:55Speaker 1: methods are both effective and patient-friendly?
- 9:58Speaker 2: This is where precision medicine If we can find a
- 10:01Speaker 2: way to integrate these new.
- 10:02Speaker 1: Methods, without causing unnecessary strain. That would be a win.
- 10:23Speaker 2: Exactly. The future research needs to focus on developing integrative approaches.
- 10:29Speaker 2: It's about leveraging the best of current technologies while being
- 10:32Speaker 2: mindful of broader implications.
- 10:34Speaker 1: That brings us to the end of today's episode. Thank
- 10:37Speaker 1: you so much for spending part of your day with us.
- 10:40Speaker 1: If you found today's discussion helpful, please take a moment
- 10:43Speaker 1: to hit the subscribe button to stay hooked in for
- 10:45Speaker 1: future episodes.
- 10:47Speaker 2: Absolutely. And if you are ever in a position to
- 10:49Speaker 2: support our efforts, small donations are always welcome. You can
- 10:54Speaker 2: find a link in the episode description to buy us
- 10:56Speaker 2: a coffee or contribute what you can.
- 10:58Speaker 1: Take care of yourself, stay balanced, and we will talk
- 11:03Speaker 1: again soon.